White matter hyperintensities are no major confounder for alzheimer's disease cerebrospinal fluid biomarkers by van Waalwijk van Doorn, Linda J C et al.
White matter hyperintensities are no major confounder for 
alzheimer's disease cerebrospinal fluid biomarkers
Article  (Accepted Version)
http://sro.sussex.ac.uk
van Waalwijk van Doorn, Linda J C, Ghafoorian, Mohsen, van Leijsen, Esther M C, Claassen, 
Jurgen A H R, Arighi, Andrea, Bozzali, Marco, Cannas, Jorge, Cavedo, Enrica, Eusebi, Paolo, 
Farotti, Lucia, Fenoglio, Chiara, Fortea, Juan, Frisoni, Giovanni B, Galimberti, Daniela, Greco, 
Viviana et al. (2020) White matter hyperintensities are no major confounder for alzheimer's 
disease cerebrospinal fluid biomarkers. Journal of Alzheimer's Disease. pp. 1-13. ISSN 1387-
2877 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/95713/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 




White matter hyperintensities are no major confounder for Alzheimer’s disease CSF biomarkers 
 
Linda J.C. van Waalwijk van Doorna,b, Mohsen Ghafoorianc, Esther M.C. van Leijsena, Jurgen A.H.R. 
Claassend, Andrea Arighie, Marco Bozzalif,g, Jorge Cannash, Enrica Cavedoi,j, Paolo Eusebik, Lucia 
Farottik, Chiara Fenogliol, Juan Forteam,n, Giovanni B. Frisonii,o, Daniela Galimbertie,l, Viviana Grecop,q, 
Sanna-Kaisa Herukkar, Yawu Liur, Alberto Lleóm,n, Alexandre de Mendonçah, Flavio M. Nobilis,t, Lucilla 
Parnettik, Agnese Piccos, Maria Pikkarainenr, Nicola Salvadorik, Elio Scarpinie,l, Hilkka Soininenr, 
Roberto Tarduccik, Andrea Urbanip,q, Eduard Vilaplanam,n, Olga Meulenbroekd, Bram Platelc, Marcel 
M. Verbeeka,b§*, H. Bea Kuiperija,b* 
 
aDepartment of Neurology, bDepartment of Laboratory Medicine, cDepartment of Radiology and 
Nuclear Medicine, dDepartment of Geriatrics, Donders Institute for Brain, Cognition and Behaviour, 
Radboud Alzheimer Centre, Radboud University Medical Center, Nijmegen, the Netherlands; 
eFondazione IRCCS Ca’ Granda, Ospedale Policlinico, Milan, Italy; fIRCCS Fondazione Santa Lucia, 
Rome, Italy; gDepartment of Neuroscience, Brighton and Sussex Medical School, University of Sussex, 
Brighton, United Kingdom; hFaculty of Medicine, University of Lisbon, Lisbon, Portugal; iLaboratory of 
Epidemiology, Neuroimaging and Telemedicine, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, 
Italy; jSorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière 
Hospital, Boulevard de l'hôpital, Paris, France; Qynapse, Paris, France; kSection of Neurology, Center 
for Memory Disturbances, University of Perugia, Perugia, Italy; lUniversity of Milan, Dino Ferrari 
Center, Milan, Italy; mSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i 
Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, 
Spain; nCenter of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), 
Madrid, Spain; oUniversity Hospitals and University of Geneva, Geneva, Switzerland; pFondazione 
Policlinica Universitario “A. Gemelli” – IRCCS, Rome, Italy; qDepartment of basic biotechnological 
sciences, intensivological and perioperative clinics, Università Cattolica, Rome, Italy; rDepartment of 
2 
 
Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland; 
sDepartment of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy; tIRCCS Ospedale 
Policlinico San Martino, Genoa, Italy;  
 
* Shared last author, both authors contributed equally to this manuscript 
 
§ Corresponding author: Dr. Marcel M. Verbeek, TML, r.830, Department of Neurology, Radboud 
University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands, Phone: +31 24 36 
14567, Fax: +31 2436 68754, E-mail: Marcel.verbeek@radboudumc.nl 
 






Background: The cerebrospinal fluid (CSF) biomarkers amyloid-β 1-42 (Aβ42), total and 
phosphorylated tau (t-tau, p-tau) are increasingly used to assist in the clinical diagnosis of 
Alzheimer’s disease (AD). However, CSF biomarker levels can be affected by confounding factors.  
Objective: To investigate the association of white matter hyperintensities (WMHs) present in the 
brain with AD CSF biomarker levels. 
Methods: We included CSF biomarker and magnetic resonance imaging (MRI) data of 172 subjects 
(52 controls, 72 mild cognitive impairment (MCI) and 48 AD patients) from 9 European Memory 
Clinics. A computer aided detection system for standardized automated segmentation of WMHs was 
used on MRI scans to determine WMH volumes. Association of WMH volume with AD CSF 
biomarkers was determined using linear regression analysis. 
Results: A small, negative association of CSF Aβ42, but not p-tau and t-tau, levels with WMH volume 
was observed in the AD (r2=0.084, p=0.046), but not the MCI and control groups, which was slightly 
increased when including the distance of WMHs to the ventricles in the analysis (r2=0.105, p=0.025). 
Three global patterns of WMH distribution, either with 1) a low, 2) a peak close to the ventricles, or 
3) a high, broadly-distributed WMH volume could be observed in brains of subjects in each diagnostic 
group. 
Conclusion: Despite an association of WMH volume with CSF Aβ42 levels in AD patients, the 
occurrence of WMHs is not accompanied by excess release of cellular proteins in the CSF, suggesting 
that WMHs are no major confounder for AD CSF biomarker assessment. 
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Alzheimer’s disease (AD) is the most prevalent form of dementia and is a progressive and 
irreversible neurodegenerative disease. Typical neuropathological lesions observed post mortem in 
the brains of AD patients are the extracellular accumulation of amyloid-β (Aβ) protein in both 
plaques and the cerebral vasculature, and the intracellular neurofibrillary tangles containing 
hyperphosphorylated tau (p-tau) protein [1]. 
Several lines of evidence suggest that vascular pathology contributes to the development and 
clinical symptoms of AD. Subcortical vascular lesions visualized by neuroimaging are collectively 
referred to as cerebral small vessel disease (SVD). Neuroimaging biomarkers of SVD comprise white 
matter hyperintensities (WMHs), lacunar infarcts and microbleeds [2]. These abnormalities can be 
observed in brains of healthy elderly individuals (typically above the age of 60 years), but are 
observed in increased numbers in AD patients, likely contributing to cognitive decline [3-7]. WMHs 
are signal abnormalities in the white matter that appear as hyperintensities on fluid-attenuated 
inversion recovery (FLAIR) T2-weighted magnetic resonance imaging (MRI) scans and are considered 
biomarkers of SVD [8-13]. WMHs are caused by destruction of the myelin sheath that envelops the 
axons of neurons. Myelin is the main component of white matter and facilitates the fast signal 
transmission along neuronal processes [14]. Lacunes of presumed vascular origin are cavities filled 
with cerebrospinal fluid (CSF), visible as round or ovoid subcortical hypointense areas of 3-15 mm on 
FLAIR T2-weighted MRI scans. Microbleeds are defined as small hypointense areas of 2-10 mm on 
T2* Gradient-Recall Echo (GRE) or Susceptibility-Weighted Imaging (SWI) MRI sequences [12]. 
CSF biomarkers (Aβ42, total tau (t-tau) and p-tau) have been shown to improve the accuracy of 
AD diagnosis to >85% and have therefore recently been included in the diagnostic criteria for AD [15-
17]. In the CSF of AD patients, the combination of decreased levels of Aβ42 and elevated 
concentrations of both t-tau and p-tau proteins can be observed, reflecting senile plaques and 
neurofibrillary tangle pathology, respectively [18] and this combination may predict the progression 
to AD dementia in patients with mild cognitive impairment (MCI) [19, 20]. In patients with vascular 
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dementia or stroke (transiently) increased CSF t-tau and decreased CSF Aβ42 levels can be observed 
[21-24]. Therefore, it is possible that SVD affects the levels of CSF Aβ and tau proteins and thus affect 
the diagnostic accuracy of these biomarkers for AD.  
This study aims to identify the relation between AD CSF biomarkers (Aβ42, t-tau and p-tau) and 
the presence of WMHs. We hypothesize that the occurrence of WMHs, especially when localized 
close to the ventricles, is accompanied by excess release of cellular components (e.g. tau proteins) in 
the extracellular space and as such can modify the patterns of biomarkers that are known to be 
associated with AD pathology.  
 
MATERIALS AND METHODS 
Subjects 
T1-weighted structural MRI scans, T2-weighted-FLAIR MRI scans and AD CSF biomarker data were 
acquired from 9 research centers within the Biomarkers for Alzheimer’s and Parkinson’s Disease 
(BiomarkAPD) project, a consortium of the European initiative Joint Programme for 
Neurodegenerative Diseases Research (JPND). The study was approved by local ethics committees or 
the institutional review board of each center. The participants or their legal representatives gave 
written informed consent. Initially, 309 subjects were included for analysis (a sub-set of a previous 
study on ventricular volumes [25], but for several reasons discussed in the results section, 137 
subjects were excluded from analysis and therefore n = 172 subjects were finally included in this 
study. 
All subjects underwent clinical and neurological assessment, lumbar puncture, MRI scanning, and 
CSF analysis at their local laboratory. The patient groups comprised: 52 neurological controls 
(including n = 34 healthy controls, n = 10 subjects for whom cognitive disorders were excluded, and n 
= 8 subjective memory complainers (SMC), based on examination of medical records), 72 MCI 
patients, of which 42 patients were diagnosed with amnestic MCI, and 48 AD patients. Diagnoses 
were defined by clinical and neurological assessment and application of diagnostic criteria (see 
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Supplementary Table 1 for the MCI and AD diagnostic criteria used in each center; the locally applied 
cut-off values for the use of the CSF biomarkers are shown in Supplementary Table 2). We decided to 
pool the healthy control subjects and SMC in one group as neurological controls. Individuals were 
labeled as SMC when they presented with cognitive complaints, and results of clinical investigations 
were within normal range. Individuals were labeled as controls if they were free of neurological 
disease. SMC are very similar to healthy controls in terms of prevalence of amyloid pathology [26]. 
CSF Aβ42 (p = 0.42), t-tau (p = 0.28) and p-tau levels (p = 0.28) as well as WMH volumes (p = 0.77) 
were similar between SMC and healthy control subjects (see supplementary Table 3). 
We collected data of the subjects who fulfilled the following quality requirements: the time 
between the lumbar puncture and the T1-weighted and T2-weighted-FLAIR MRI scans was less than 6 
months; both T1-weighted and T2-weighted-FLAIR MRI scans had a maximum voxel size of 2.0mm x 
2.0mm x 2.0mm. The T1-weighted MRI scans were used to examine the brain structure, while the T2-
weighted-FLAIR MRI scans were used for the visualization of WMHs. Additionally, information about 
age, sex, center, and scanner type were recorded. Ventricular volume and total intracranial volume 
(TIV) of each subject were previously determined ([25]; Table 1). In Supplementary Tables 4, 5 and 6, 
information on the MRI scanner type, acquisition parameters and whether a center used a specific 
MRI protocol or not, can be found. 
 
Computer aided detection of WMHs 
We pre-processed each MRI scan by a visual check. The MRI scans of unsatisfactory quality in 
terms of low transverse resolution, or low structural visibility due to movement or other sources of 
noise were excluded. Thereafter, WMHs were detected by a machine learning-based model 
(computer aided detection algorithm) [27] on the T1 and FLAIR modalities, resulting in the number of 
WMH voxels per axial-slice as outcome.  
Next, the detection of WMHs by the algorithm was visually checked by a trained reader and was 
adjusted if necessary (post-processing). An example of a structural T1-weighted MRI scan ran by the 
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computer aided detection algorithm can be found in Fig. 1. Using the number of WMH voxels per 
axial-slice and information about the voxel size (in mm2) and distance of axial-slices (in mm), the 
WMH volume (expressed in mL) per axial-slice was calculated. The total WMH volume was 
subsequently calculated by the sum of the WMH volume of each axial-slice. 
 
WMH distribution patterns 
The region from ventricles to the skull was divided in 20 layers, with each layer accounting for 5% 
of the total distance between ventricles to the skull. Data on WMH volumes was available for each of 
these circular layers; a schematic overview can be found in Fig. 2. In order to analyze the distribution 
of WMHs across the brain in a standardized manner, we used the following self-defined criteria. 
Distribution patterns of WMHs were based on AD patient data and defined as follows: low WMH 
volume in a layer was defined as <20% (<1.32 mL) of the maximum WMH volume (i.e. 6.6 mL) 
measured in any of the layers of the AD patients. WMH pattern 1 (with low WMH volumes) was 
defined as low WMH volume (<1.32 mL/layer) in each of the 20 layers of a subjects’ brain. WMH 
pattern 2 was characterized by a peak in WMH volume close to the ventricles and defined as high 
WMH volume (>1.32 mL/layer) in one or more layer(s) of the three layers closest to the ventricles, 
and low WMH volume in other layers. WMH pattern 3 comprised the remaining patterns, generally 
characterized by a high WMH volume with broad distribution over the brain, and defined as at least 
one layer distant from the ventricles (layers 4-20) with a high WMH volume (i.e. >1.32 mL). 
 
AD CSF biomarkers 
The ELISA’s from Fujirebio (Gent, Belgium) were used according to the manufacturers’ protocol 
for the determination of Aβ42 (INNOTEST® β-AMYLOID (1-42)), t-tau (INNOTEST® hTAU Ag), p-tau 
(INNOTEST® PHOSPHO-TAU (181P)) at each site separately. Locally applied cut-off values for the use 
of AD CSF biomarkers are shown in Supplementary Table 2. In all participating laboratories, the CSF 
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samples were collected in polypropylene tubes [16]. The CSF samples were transported directly to 
the laboratory, centrifuged and measured or stored at -80°C until use. 
 
Data and statistical analysis 
Statistical analyses were performed using IBM SPSS Statistics 22 (Armonk, NY, USA) and Graphpad 
Prism 5.03 (La Jolla, CA, USA). Normality of data distribution was determined using the D’Agostino 
and Pearson omnibus normality test. For comparison of two groups, a non-parametric Mann-
Whitney test was used. For comparison of three groups, the non-parametric Kruskal-Wallis test with 
Dunn’s test for multiple comparisons was used. The Chi-square test was used to check for sex 
differences between the diagnostic groups. Bivariate correlations to determine the association of 
WMH volume with the CSF biomarkers were performed using linear regression analysis based on 
normal distribution. To obtain normal distributed data for the linear regression analysis, CSF p-tau, 
CSF t-tau, WMH/TIV and the arbitrary WMH*distance values were log transformed. In the linear 
regression analysis, age and sex were analyzed as covariates, and research center, in combination 
with or without white matter volume, were subsequently included as additional covariates. The 
WMH*distance value is an arbitrary factor that combines WMH volume with the relative distance of 
WMHs to the ventricles, and was calculated using the following formula: WMH*distance = Ʃlayer [ 
WMH volume (mL) * ( 100 – relative distance to ventricles (%) ) ]. All tests were two-sided and 
statistical significance was defined as p < 0.05. 
 
RESULTS 
Exclusion of subjects during processing 
Unfortunately, during pre-processing 34 subjects had to be excluded because of movement 
artefacts, 19 subjects because of “salt and pepper” noise effect, with many small white dots 
dispersed over the images, and 31 subjects because of insufficient resolution of the MRI scans. 
Furthermore, after the processing phase 25 subjects had to be excluded because no data could be 
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obtained due to an algorithm error when the MRI scans of these subjects were run by the computer 
aided detection system. Moreover, during post-processing 13 subjects had to be excluded due to 
WMH segmentation failures and another 13 subjects were excluded due to algorithm failures. A 
segmentation failure is a failure in the algorithm used for the segmentation of ventricles, while an 
algorithm failure could be a failure in any of the automated steps (e.g. multi-modal registration, brain 
extraction, bias field correction, intensity standardization), which potentially have significant impact 
on the quality of the WMH detection results. Finally, two more patients were excluded for other 
reasons; one patient due to extreme high WMH volume (116 mL) and another patient with a non-
realistic high p-tau value (690 pg/mL). Comparison of available demographic and CSF biomarker data 
showed that, apart from minor differences in CSF p-tau and t-tau levels in control subjects, these 
data were comparable between the groups of excluded versus included control, AD and MCI 
subjects. Thus 172 subjects remained in the study and their demographics are shown in Table 1. In 
Supplementary Table 7 the detailed overview of included and excluded patients per center can be 
viewed. 
 
Clinical validation of AD CSF biomarkers 
The Aβ42 CSF concentrations were significantly decreased (p < 0.001) in AD patients (mean: 482 ± 
194 pg/mL) compared to control subjects (mean: 757 ± 193 pg/mL) and MCI patients (mean: 706 ± 
334 pg/mL) (Fig. 3A). The p-tau (Fig. 3B) and t-tau (Fig. 3C) concentrations were significantly 
increased (p < 0.001) in AD patients (mean p-tau: 95 ± 51 pg/mL, mean t-tau: 713 ± 527 pg/mL) and 
MCI patients (mean p-tau: 81 ± 61 pg/mL, mean t-tau: 492 ± 294 pg/mL) compared to control 
subjects (mean p-tau: 42 ± 15 pg/mL, mean t-tau: 225 ± 104 pg/mL). Table 1 provides an overview of 
the CSF data of all patient groups. 
 
WMH volume and distribution in the diagnostic groups 
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No significant differences (p = 0.18) were observed in the mean WMH volume between the 
different diagnostic groups (controls, MCI and AD), see Fig. 4A. We additionally analyzed the 
distribution of WMH volume measured in the various layers of the MRI scans (Fig. 4B). Overall, a 
similar distribution of WMH volume across the brain was observed for the three diagnostic groups, 
with a peak WMH volume relatively close to the ventricles (relative distance; at 5-10% of the distance 
between ventricles and brain skull).  
 
Association of AD CSF biomarkers with WMH 
We used linear regression analysis to study the association of AD CSF biomarkers with WMH 
volume. In these analyses, WMH volume was corrected for the size of the head (TIV). A small, 
negative correlation between CSF Aβ42 levels and WMH/TIV was observed. I.e., higher CSF Aβ42 
levels were associated with slightly, but significantly, lower WMH/TIV values in the AD group (r2 = 
0.084, p = 0.046; Fig. 5A), but not in the MCI (r2 = 0.00, p = 0.98) or control group (r2 = 0.066, p = 
0.065; correlation data in Table 2). These results for the control group remained similar after 
exclusion of SMC (n = 8) from this group (r2 = 0.037, p = 0.21). Subgroup analysis showed that in MCI 
patients positive for CSF Aβ42 (i.e. with decreased levels based on the local cut-off values; Table 1 
and supplementary Table 2) CSF Aβ42 levels tended to associate with WMH/TIV values (n = 26, r2 = 
0.14, r = -0.38, p = 0.056), which was not the case in MCI patients negative for CSF Aβ42 (n = 46, r2 = 
0.00, r = -0.01, p = 0.97). In contrast, no association of p-tau or t-tau with WMH/TIV was observed in 
the AD (Fig. 5B-C), MCI or the control groups (correlation data in Table 2). We sequentially added 
several covariates to the analyses, first age and sex, second center and third total white matter 
volume. The association of Aβ42 levels with WMH/TIV in the AD group remained significant when 
age and sex in combination with the center and total white matter volume were included as 
covariates (overall model: p = 0.045, r2 = 0.230; significance of WMH/TIV in the model: p = 0.031). 
We repeated the linear regression analysis using an arbitrary factor that combines WMH volume 
with the relative distance of WMHs to the ventricles instead of WMH/TIV. This arbitrary 
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WMH*distance value assigns a higher value to WMH volumes closer to the ventricles. Like for the 
association with WMH volume, we only observed a significant, negative correlation for CSF Aβ42 
with this arbitrary WMH*distance value in the AD group (r2 = 0.105, p = 0.025), which remained after 
including age, sex, center and white matter volume as covariates (overall model: p = 0.025, r2 = 0.252; 
significance of WMH*distance in the model: p = 0.016). 
 
Association of WMH distribution patterns with CSF biomarker levels 
To study the relation between WMH distance to the ventricles and CSF biomarker levels in more 
detail, we looked at the WMH distribution patterns within a diagnostic group. In the AD group, we 
could observe three global patterns in the distribution of WMH volume within the brain. The most 
abundant pattern (pattern 1, Fig. 6A) had an overall low WMH volume across the brain. The second 
most abundant pattern (pattern 2, Fig. 6B) showed a peak in WMH volume close to the ventricles 
and a low WMH volume comparable to pattern 1 distant from the ventricles, whereas the last 
pattern (pattern 3, Fig. 6C) showed a high WMH volume distributed over a broader range of the 
brain. The WMH volume was significantly higher for AD patients with pattern 3 as compared to 
pattern 1 and 2, as well as for AD patients with pattern 2 compared to pattern 1 (Fig. 6D). The three 
WMH patterns could also be observed in MCI patients with comparable WMH peak volumes per 
pattern (Table 3). In control subjects patterns 1 and 2 were also frequently observed, in contrast to 
pattern 3 which was observed only in two control subjects (Table 3). 
We compared patients with WMH pattern 2, i.e. WMH close to the ventricles, to patients with 
WMH pattern 3, i.e. WMH both close and distant from the ventricles. We observed significantly 
decreased levels of Aβ42, but no differences in t-tau or p-tau levels, in AD patients with WMH 
pattern 3 (mean Aβ42: 404 ± 103 pg/mL) as compared to pattern 2 (mean Aβ42: 514 ± 146 pg/mL; p 
= 0.032, Fig. 6E). We neither observed differences in Aβ42 nor in t-tau or p-tau levels between these 
patterns 2 and 3 in MCI patients (Fig. 6F-G and data not shown). The analysis could not be performed 
for control subjects, since only few subjects with WMH pattern 3 were available. 
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We also compared patients with WMH pattern 1 to patients with WMH pattern 2 or 3, but we did 
not observe any significant differences in these comparisons for Aβ42, t-tau and p-tau levels in 
controls, MCI or AD patients (data not shown). Ventricular volumes were, however, significantly 
increased in MCI and AD patients with WMH pattern 2 or 3 versus WMH pattern 1 (MCI: 50.5 ± 24.1 
mL vs. 30.0 ± 13.6 mL, p < 0.001; AD: 49.6 ± 25.6 mL vs. 32.9 ± 13.8 mL, p = 0.009, Fig. 6H), and weak, 
but significant, correlations between ventricular and WMH volumes were observed for all three 
patient groups separately and combined (all: Spearman r = 0.405, p < 0.001). 
 
DISCUSSION 
CSF biomarkers have obtained an increasingly prominent position in support of establishing the 
early clinical diagnosis of AD, and can also support in predicting progression of AD [20]. Establishing 
and controlling for confounding factors, may further optimize the performance of CSF biomarkers. In 
a previous study we demonstrated that ventricular volume can be a confounding factor. We showed 
a slight, but significant, improved diagnostic value of Aβ42 after correction for ventricular volume 
[25]. In the current study we evaluated WMHs as possible confounding factor for AD CSF biomarkers 
(Aβ42, t-tau, p-tau).  
 
Association of AD CSF biomarkers with WMH volume 
We hypothesized that the occurrence of WMHs is accompanied by the excess release of cellular 
components (e.g. tau proteins) in the extracellular space and as a result can modify the patterns of 
biomarkers that are known to be associated with AD pathology. Unlike this hypothesis, we showed 
that increased WMH volume, albeit weakly, was significantly associated with decreased CSF Aβ42 
concentrations in the AD group. This finding suggests that increased WMH volume is associated with 
worsened amyloid pathology. We did not observe an association between p-tau or t-tau 
concentrations and WMH volume in any group, nor between CSF Aβ42 levels and WMH volume in 
the MCI and control groups. Our findings are not in line with a previous study in which it was shown 
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that decreased CSF Aβ42 and increased neurofilament light chain levels are related to increased 
WMH volume in a cohort of cognitively intact elderly individuals [28]. Additionally, two other studies 
also reported a significant negative correlation (p<0.01; p=0.013) between CSF Aβ42 and WMH 
volume in cognitively normal individuals and MCI patients [29, 30]. In all three studies, no AD group 
was included [28-30]. Recently, another study showed a significant negative association of CSF Aβ42 
levels with WMH volume in (healthy) controls and SMCs, and a border-significant association in MCI 
and AD patients [31]. No associations between vascular risk factors and CSF Aβ42 levels in cognitively 
normal older individuals and individuals with abnormal biomarkers were found in another study [32]. 
The absence of an association of CSF Aβ42 levels with WMH volume in our study may be due to the 
heterogeneity of our MCI group and thus high variability in Aβ42 levels observed in these patients. 
CSF Aβ42 levels in our MCI group were not significantly decreased compared to control subjects, 
which is also reflected by a relative low number of MCI patients (36%) positive for Aβ42 (i.e. with 
decreased CSF Aβ42 level). Indeed, a subgroup in our study diagnosed with amnestic MCI (who are 
more likely to convert to AD) had significantly lower CSF Aβ42 levels (mean: 680 pg/ml) as compared 
to the control group (p < 0.05), and had a higher number of patients (48%) positive for Aβ42 than the 
whole MCI group, which is in line with previous studies [33, 34]. 
Our finding of the absence of a correlation between p-tau or t-tau and WMH volume is consistent 
with previous studies [28, 29, 31, 35-38]. Tau is mainly localized in axons, and increased CSF t-tau 
levels reflect neurodegeneration (formation of neurofibrillary tangles) or neuronal injury and may 
dominate the potentially more subtle effects of WMHs on tau protein release [28, 38]. However, 
another study showed an association between vascular risk burden measured by the Framingham 
Stroke Risk Profile (including WMHs, silent cerebral infarcts and microbleeds) and axonal damage, 
which was more pronounced in patients with AD pathology [39]. Thus, it cannot be excluded that 
SVD may affect t-tau levels in CSF if other measures of SVD beyond WMHs are included. However, 
these data were not available for the current study. 
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We aimed to study also the relation of the distance of WMHs to the ventricles with AD CSF 
biomarkers in addition to the WMH volume. WMHs may represent an independent indicator of 
cerebrovascular impairment in AD patients and may interact with AD pathology [40]. We expected a 
greater exchange of proteins and influence of WMHs when these are close to the ventricles, where 
most of the CSF is located, as opposed to more distant WMHs. Hereto, we used an arbitrary value 
that combined both aspects. We observed a slightly stronger association with CSF Aβ42 levels in the 
AD group when this arbitrary value was used instead of total WMH volume only. This suggests that 
the relative distance of WMH to the ventricles contributes to the extent of the association with CSF 
Aβ42 levels. To explore this further, we analyzed the WMH distribution pattern across the brain. We 
could observe three different distribution patterns. Interestingly, CSF Aβ42 levels were lower in AD 
patients with a broad distribution of WMH across the brain (pattern 3) as compared to AD patients 
with a higher WMH volume only close to the ventricles (pattern 2), further suggesting a possible 
relation of WMH distance to ventricles with CSF Aβ42 levels. However, the total WMH volume in 
brains of patients with the broad distribution pattern 3 was also higher than for patients with a peak 
volume close to the ventricles, and therefore the association of either total WMH volume and 
distance of WMH lesion from the ventricles could not be separately assessed.  
 
Limitations 
The results of this study should be interpreted with caution for a number of reasons. Firstly, CSF 
biomarker concentrations were determined in different laboratories and, despite that the same 
assays were used, variation in the pre-analytical and analytical procedures used will influence our 
data [16, 41]. Efforts for more standardized methods are needed to measure CSF biomarkers, and 
standardized guidelines are developed using uniform reference materials within the JPND-
BiomarkAPD project (http://biomarkapd.org/). Secondly, there was neither a standardized MRI 
protocol used for this study nor were the patients scanned using the same scanner. Therefore, it 
cannot be excluded that variations in scanning protocol have influenced our data. Thirdly, we have 
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not evaluated the possible correlations between CSF biomarker levels and disease progression of AD. 
Patients at a more advanced stage of AD may have both increased WMH volumes and decreased CSF 
Aβ42 levels compared to patients at earlier stages of disease. Indeed, a systematic literature review 
showed a trend in which CSF Aβ42 decreases (mean: -0.4 pg/mL/month for 8 studies) over time [42]. 
In contrast, however, in a longitudinal study no changes were observed in CSF Aβ42 and p-tau levels 
over time (mean: 24 ± 13 months) in MCI and AD patients [43]; therefore, it remains uncertain to 
what degree the association of WMHs with CSF Aβ42 can be explained by differences in disease 
stage. Fourthly, the MCI group in our study is a mixed group and may include both stable MCI 
patients and MCI patients who will convert to AD at a later stage, which may have affected our 
findings. Furthermore, some laboratories used CSF biomarkers as support in the clinical diagnosis of 
MCI (and AD), while other laboratories did not. It should be noted that the proportion of Aβ42-
positive cases was comparable when the diagnosis was supported by CSF biomarkers versus when 
CSF biomarkers were not used to support the diagnosis. Finally, it would be interesting to study the 
association of WMHs with CSF biomarkers in a larger population and to include additional CSF 
biomarkers like Aβ40 or covariates like APOE genotype, as well as to develop a model combining 
different confounding factors to evaluate their combined relation with diagnostic accuracy of CSF 
biomarkers. We did, unfortunately, not have CSF Aβ40 or APOE genotype data available to include in 
analyses of the current study.  
 
Conclusion 
In summary, we studied if the differences in WMH volume may act as a confounding factor for 
interpretation of CSF biomarkers. For this purpose we used a computer aided detection algorithm for 
the automated measurement of WMHs. We showed that  WMH volume, albeit weakly, associated 
with CSF Aβ42 concentrations in AD, but not in controls and MCI patients. Interestingly, three global 
patterns in the distribution of WMH volume within the brain could be observed in AD patients. Our 
data suggests that the distance of WMH to the ventricles in addition to WMH volume also slightly 
16 
 
contributes to the association with CSF Aβ42 levels. In conclusion, since only CSF Aβ42 levels weakly 
and negatively correlated with WMH/TIV, the occurrence of WMHs is not accompanied by excess 
release of cellular components (tau and Aβ proteins) in the CSF. Therefore, WMHs are no major 
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Table 1. Demographic data and CSF biomarker concentrations across the diagnostic groups 
  Control  AD MCI p-value 
Sample size: n  52 48 72 
 
Sex: female, n (%)  34 (65) 29 (60) 44 (61) 0.850a 
Age: years, mean (SD)  61.1 (8.9) 69.0 (8.2) 69.8 (6.8) <0.0001b 
Aβ42: mean, pg/mL (SD) 
     [Aβ42-positive, %]d 
757 (193) 
     [12 %] 
482 (194) 
     [79 %] 
706 (334) 
     [36 %] 
<0.0001b 
 
t-tau: mean, pg/mL (SD)c 
     [t-tau-positive, %]d 
225 (104) 
     [13 %] 
713 (527) 
     [77 %] 
492 (294) 
     [57 %] 
<0.0001b 
 
p-tau: mean, pg/mL (SD) 
     [p-tau-positive, %]d 
42 (15) 
     [4 %] 
95 (51) 
     [60 %] 
81 (61) 
     [47 %] 
<0.0001b 
 
# of WMH: mean, n (SD) 132 (75) 99 (118) 89 (63) 0.0007b 
WMH volume: mean, mL (SD) 5.7 (3.1) 9.0 (7.9) 8.7 (7.8) 0.183b 
WM: mean, mL (SD) 515 (80) 540 (79) 550 (92) 0.056b 
VV: mean, mL (SD) 23 (15) 42 (23) 40 (22) <0.0001b 
TIV: mean, mL (SD) 1346 (139) 1363 (118) 1374 (121) 0.364b 
Abbreviations: CSF, Cerebrospinal fluid; AD, Alzheimer's disease; MCI, mild cognitive impairment; SD, 
standard deviation; Aβ42, amyloid-β; t-tau, total tau; p-tau, phosphorylated tau; # of WMH, number 
of white matter hyperintensities; WM, white matter; VV, ventricular volume; TIV, total intracranial 
volume.  
a Chi-square test. 
b Kruskal-Wallis with Dunn’s post hoc test. 
c Not available for n=1 AD and n=3 MCI patients 
d Based on local cut-off values 
27 
 
Table 2. Correlation between WMH volume & AD CSF biomarkers 
 
Aβ42 p-tau t-tau 
 
p-value r r2 p-value r r2 p-value r r2 
Control 0.065 -0.258 0.066 0.443 0.109 0.012 0.490 0.098 0.010 
MCI 0.975 0.004 0.000 0.250 0.137 0.019 0.530 0.077 0.006 





Table 3. WMH pattern characteristics and distribution per patient group 
 
All (n) WMH pattern 1 WMH pattern 2 WMH pattern 3 
Control         
     n (% of total) 52 30 (58%) 20 (38%) 2 (4%) 
     mean WMH peak volume* 
 
0.76 ± 0.25 1.38 ± 0.47 2.65 ± 1.36 
MCI 
    
     n (% of total) 72 36 (50%) 19 (26%) 17 (24%) 
     mean WMH peak volume* 
 
0.71 ± 0.36 1.62 ± 0.50 3.00 ± 1.25 
AD 
    
     n (% of total) 48 21 (44%) 16 (33%) 11 (23%) 
     mean WMH peak volume*   0.66 ± 0.30 1.59 ± 0.54 2.82 ± 1.79 
* Highest (peak) mean WMH volume (in mL ± SD) in a layer per pattern, which was for each pattern 
and patient group the WMH volume in layer 2. See the Materials and Methods section for a definition 







Fig. 1. WMH detection on a structural MRI scan 
Segmentation of the WMHs detected by the computer aided detection system in the transverse 
plane projected on a T1-weighted MRI scan of an AD patient. Periventricular WMHs are indicated in 
red. Of note, the green circumference indicates a false positive WMH and was removed during post-
processing. 
 
Fig. 2. WMH layers in a schematic overview 
Brain tissue was divided into 20 layers, from ventricles to the skull, with each layer accounting for 5% 
of the total distance between ventricles to the skull. To exemplify this division the first three circular 
layers around the ventricles are shown in this schematic picture. Brain section image was modified 
from Smart Servier Medical Art, https://smart.servier.com. 
 
Fig. 3. Analysis of AD CSF biomarkers: Aβ42 (n = 172), p-tau (n = 172) and t-tau (n = 168) in healthy 
controls, MCI and AD patients 
Analysis of (A) Aβ42 in healthy controls (n = 52), Mild Cognitive Impairment (MCI) (n = 72) and 
Alzheimer’s disease (AD) patients (n = 48), (B) p-tau in healthy controls (n = 52), MCI (n = 72) and AD 
patients (n = 48) and (C) t-tau in healthy controls (n = 52), MCI (n = 69) and AD patients (n = 47). Solid 
bar = median; p-value: ***, p < 0.001 (Kruskal-Wallis with Dunn’s post hoc test). 
 
Fig. 4. WMH volume per diagnostic group  
(A) WMH volume per diagnostic group: healthy controls (n = 52), Mild Cognitive Impairment (MCI) (n 
= 72) and Alzheimer’s disease (AD) patients (n = 48). No significant differences were found between 
the diagnostic groups (p = 0.18). Solid bar = median. (B) WMH volume distribution as a function of 
the relative distance to the ventricles, per diagnostic group. Healthy controls had a lower WMH 




Fig. 5. Correlation of WMH volume with CSF Aβ42, t-tau and p-tau  
White matter hyperintensity volumes corrected for total intracranial volume (WMH/TIV) versus CSF 
Aβ42 (A, D, G), p-tau (B, E, H) and t-tau (C, F, I) concentrations in the Alzheimer’s disease (AD) group 
(A-C), the mild cognitive impairment (MCI) group (D-F) and the control group (G-I). A significant (p < 
0.05), negative correlation was found between (log) WML/TIV and CSF Aβ42 concentrations in the 
AD group (A), but not for (log) p-tau or (log) t-tau in any group or for Aβ42 in the MCI and control 
groups. P and r values derived from linear regression analyses are plotted. Linear regression lines are 
shown, except for panel A and G where quadratic relations are shown. 
 
Fig. 6. WMH distribution patterns in brains of AD patients 
WMH in brains of AD patients showed either (A) a distribution of a low WMH volume across the 
whole brain (pattern 1), or (B) an increased WMH volume (peak) close to the ventricles only (pattern 
2), or (C) a high WMH volume distributed across a broader region of the brain (pattern 3). The WMH 
volume is shown per brain layer for a total of 20 evenly distributed layers per brain (indicated as 
relative distance from the ventricles in %). The distribution pattern for each patient is shown in grey, 
with the mean WMH volume per layer for each pattern shown in black. (D) Dot plot of the total 
WMH volumes in the brain of AD patients per WMH pattern. Mean WMH volumes were statistically 
significant different between the three patterns (Kruskal Wallis test with Dunn’s test for multiple 
comparisons). Aβ42 CSF levels (E), but not t-tau (F) and p-tau levels (G), were significantly decreased 
in AD patients with WMH pattern 3 compared to pattern 2. (H) Ventricular volume was significantly 
increased in AD patients with WMH pattern 2 or 3 (high WMH volumes) compared to pattern 1 (low 

































Supplementary Table 1: Overview of diagnostic criteria 
Research centers Diagnostic criteria 
CSF biomarkers used as 
support in diagnosis? 
1 Radboudumc 
AD: [1, 2] 
Yes 
MCI: [3, 4] 
2 Hospital de Sant Pau MCI: [3, 4] No 
3 









5 University of Eastern Finland (UEF) 
Dementia: [6] 
No AD: [1] 
MCI: [3] 
6 University of Genoa AD: [7, 8] Yes 





University of Milan, Fondazione Ca’ 
Granda IRCCS Ospedale Policlinico 
AD: [7, 8] 
Yes 
MCI: [3] 








Supplementary Table 2: Overview of cut-off values of CSF biomarker concentrations 
Research 
centers 
Assay type Aβ42 (ng/L) t-tau (ng/L) p-tau (ng/L) 
Definition of cut-off 
point for abnormal 
1 Fujirebio ELISA ≤ 500* ≥ 350** ≥ 85 
Defined from population 
of healthy controls 
2 Fujirebio ELISA ≤ 550 ≥ 350 ≥ 61 ROC curve [9] 
3 Fujirebio ELISA ≤ 500 ≥ 500*** ≥ 70 Rank-based [10] 
4 Fujirebio ELISA ≤ 445 ≥ 300 ≥ 61 ROC curve  
5 Fujirebio ELISA ≤ 450 ≥ 400 ≥ 70 ROC curve  
6 Fujirebio ELISA ≤ 600 ≥ 300-400 ≥ 40 ROC curve 
7 Fujirebio ELISA ≤ 500 ND ≥ 40 Unknown 
8 Fujirebio ELISA ≤ 500 ≥ 500*** ≥ 61 Rank-based [10] 
9 Fujirebio ELISA ≤ 800 ≥ 300 ≥ 60 Rank-based [10] 
Key: CSF, cerebrospinal fluid; Aβ42, amyloid-β; t-tau, total tau; p-tau, phosphorylated tau; ROC, 
receiver operating characteristic; ND, not determined. 
* Aβ42: age < 15: ≤ 400 ng/L; age > 15: ≤ 500 ng/L. 
** t-tau: age < 50: ≥ 300 ng/L; age > 50: ≥ 350 ng/L. 




Supplementary Table 3: Comparison of control and SMC subjects 
 Controls  SMCs p-value* 
Sample size: n  44 8 
 
CSF Aβ42: mean, ng/L (SD) 746 (191) 817 (209) 0.417 
CSF t-tau: mean, ng/L (SD) 41 (15) 48 (18) 0.275 
CSF p-tau: mean, ng/L (SD) 214 (89) 287 (156) 0.281 
WMH volume: mean, mL (SD) 5.59 (2.87) 6.45 (4.15) 0.771 
Key: SMC, subjective memory complainers; CSF, cerebrospinal fluid; SD, standard deviation; Aβ42, 
amyloid-β; t-tau, total tau; p-tau, phosphorylated tau; WMH, white matter hyperintensities.  





Supplementary Table 4: Overview of MRI scanners 
Research centers Type of MRI scanner Company Magnetic field (Tesla) Protocol 
1 
Magnetom Avanto 1 SIEMENS 1.5 T 1 protocol, acquisition matrix 192x256 
Magnetom Avanto 2 SIEMENS 1.5 T 1 protocol, acquisition matrix 192x256 
Magnetom TrioTim SIEMENS 3.0 T 1 protocol, acquisition matrix 192x256 
2 ACHIEVA X-series PHILIPS 3.0 T 1 protocol, acquisition matrix 240x234 
3 Signa HDxt GE HealthCare 1.5 T 1 protocol, acquisition matrix 256x256 
4 Signa HDxt GE HealthCare 1.5 T  No protocol  
5 Magnetom Vision plus SIEMENS 1.5 T  4 protocols, acquisition matrix 256x256  
6 
Genesis Signa GE HealthCare 1.5 T No protocol 
Signa Excite GE HealthCare 1.5 T No protocol 
Signa HDxt GE HealthCare 1.5 T No protocol 
Signa HDxt GE HealthCare 3.0 T No protocol 
ACHIEVA A-series 1 PHILIPS 1.5 T No protocol 
ACHIEVA A-series 2 PHILIPS 1.5 T No protocol 
ACHIEVA A-series 3 PHILIPS 1.5 T No protocol 
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7 Magnetom Allegra SIEMENS 3.0 T 1 protocol, acquisition matrix 224x256 
8 ACHIEVA X-series PHILIPS 3.0 T 1 protocol, acquisition matrix 272x268 





Supplementary Table 5: Overview of MRI scanner characteristics 
Research centers 
T1-weighted MRI parameters 
TR (ms) TE (ms) Flip angle (°) Matrix size Voxel size (mm³) 
1* 1900 3.42 15 192x256 1.0x1.0x1.0 
2 8.1 3.7 8 240x234 1.0x1.0x1.0 
3 11.6 5.1 8 256x256 1.0x1.0x1.0 
4 NA NA NA NA Max. 2.0x2.0x2.0 
5 9.7 4.0 10 256x256 1.0x1.0x1.0 
6* NA NA NA NA Max. 2.0x2.0x2.0 
7 1338 2.4 15 224x256 1.0x1.0x1.0 
8 596.4 15 69 272x268 1.0x1.0x1.0 
9 8.0 3.7 0 256x256 1.0x1.0x1.0 
Key: TR, repetition time; TE, echo time; NA, not applicable (no protocol was used). * Different 




Supplementary Table 6: Overview of MRI scanner characteristics 
Research centers 
T2-weighted-FLAIR MRI parameters 
TR (ms) TE (ms) Flip angle (°) Matrix size Voxel size (mm³) 
1* UN UN UN UN Max. 2.0x2.0x2.0 
2 11000 120 0 240x138 1.0x1.0x1.0 
3 10000 100 0 256x256 1.0x1.0x1.0 
4 NA NA NA NA Max. 2.0x2.0x2.0 
5 9000 119 0 256x256 1.0x1.0x1.0 
6* NA NA NA NA Max. 2.0x2.0x2.0 
7 8170 96 180 256x192 1.0x1.0x1.0 
8 8000 125 90 227x260 1.0x1.0x1.0 
9 9000 90 0 256x256 1.0x1.0x1.0 
Key: TR, repetition time; TE, echo time; UN, unknown, data was not available; NA, not applicable (no 




Supplementary Table 7: Detailed overview of patients 
Research centers 
Total (n) Control (n) MCI (n) AD (n) 
Included Excluded Included Included Included 
1 48 34 11 13 24 
2 49 10 39 10 0 
3 22 24 1 12 9 
4 1 20 0 1 0 
5 18 9 0 18 0 
6 11 10 1 4 6 
7 4 7 0 3 1 
8 1 15 0 0 1 
9 18 8 0 11 7 
Total 172 137 52 72 48 
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